Compare JJSF & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | MNKD |
|---|---|---|
| Founded | 1971 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2004 |
| Metric | JJSF | MNKD |
|---|---|---|
| Price | $90.84 | $5.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $138.33 | $10.08 |
| AVG Volume (30 Days) | 314.8K | ★ 3.1M |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 3.36 | 0.10 |
| Revenue | ★ $1,583,233,000.00 | $313,787,000.00 |
| Revenue This Year | $5.42 | $21.54 |
| Revenue Next Year | $2.64 | $22.21 |
| P/E Ratio | ★ $27.52 | $58.48 |
| Revenue Growth | 0.54 | ★ 17.43 |
| 52 Week Low | $80.67 | $3.38 |
| 52 Week High | $173.59 | $7.07 |
| Indicator | JJSF | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 61.66 |
| Support Level | $90.80 | $4.93 |
| Resistance Level | $94.05 | $5.81 |
| Average True Range (ATR) | 2.95 | 0.17 |
| MACD | 0.60 | 0.07 |
| Stochastic Oscillator | 72.72 | 86.36 |
J&J Snack Foods Corp manufactures, markets, and distributes snack foods and beverages to foodservice and retail supermarket outlets. The company's products include frozen beverages, juice, fruit bars, sorbet, cakes, and cookies that are distributed to various consumers, including restaurants, supermarkets, convenience stores, universities, theaters, and theme parks. The company operates in three business segments: food service, which sells snacks, desserts, and baked goods at the point-of-sale; retail supermarkets, which sells frozen and prepackaged products to supermarkets; and frozen beverages, which sells frozen beverages under brands Icee, Slush puppie, and Parrot ice in the United States, Mexico, and Canada.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.